Literature DB >> 7534590

Carboxymethyl benzylamide dextrans inhibit breast cell growth.

R Bagheri-Yarmand, P Bittoun, J Champion, D Letourneur, J Jozefonvicz, S Fermandjian, M Crépin.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1994        PMID： 7534590     DOI： 10.1007/bf02639391

Source DB:  PubMed          Journal:  In Vitro Cell Dev Biol Anim        ISSN： 1071-2690            Impact factor:   2.416


× No keyword cloud information.
  16 in total

1.  Inhibitory effects of dextran derivatives in vitro on the growth characteristics of premalignant and malignant human mammary epithelial cell lines.

Authors:  R Bagheri-Yarmand; J F Morere; D Letourneur; J Jozefonvicz; L Israel; M Crepin
Journal:  Anticancer Res       Date:  1992 Sep-Oct       Impact factor: 2.480

2.  Inhibition of growth factor binding and intracellular Ca2+ signalling by dextran sulfates of different sizes and degrees of sulfation.

Authors:  G Powis; M Seewald; M Hoke
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

3.  Molecular weight dependency of the acquired anticomplementary and anticoagulant activities of specifically substituted dextrans.

Authors:  B Crepon; F Maillet; M D Kazatchkine; J Jozefonvicz
Journal:  Biomaterials       Date:  1987-07       Impact factor: 12.479

4.  Effect of collagen and acid polysaccharides on the growth of BHK-21 cells in semi-solid media.

Authors:  F K Sanders; J D Smith
Journal:  Nature       Date:  1970-08-01       Impact factor: 49.962

5.  Tumor growth dependent on Kaposi's sarcoma-derived fibroblast growth factor inhibited by pentosan polysulfate.

Authors:  A Wellstein; G Zugmaier; J A Califano; F Kern; S Paik; M E Lippman
Journal:  J Natl Cancer Inst       Date:  1991-05-15       Impact factor: 13.506

6.  Inhibition of rat cervical epithelial cell growth by heparin and its reversal by EGF.

Authors:  T C Wright; T V Johnstone; J J Castellot; M J Karnovsky
Journal:  J Cell Physiol       Date:  1985-12       Impact factor: 6.384

7.  Inhibitory effect of substituted dextrans on MCF7 human breast cancer cell growth in vitro.

Authors:  J F Morere; D Letourneur; P Planchon; T Avramoglou; J Jozefonvicz; L Israel; M Crepin
Journal:  Anticancer Drugs       Date:  1992-12       Impact factor: 2.248

8.  Suramin inhibits the growth of human rhabdomyosarcoma by interrupting the insulin-like growth factor II autocrine growth loop.

Authors:  C P Minniti; M Maggi; L J Helman
Journal:  Cancer Res       Date:  1992-04-01       Impact factor: 12.701

9.  Anticoagulant activity of dextran derivatives. Part I: Synthesis and characterization.

Authors:  M Mauzac; J Jozefonvicz
Journal:  Biomaterials       Date:  1984-09       Impact factor: 12.479

10.  Heparin prevents vascular smooth muscle cell progression through the G1 phase of the cell cycle.

Authors:  C F Reilly; M S Kindy; K E Brown; R D Rosenberg; G E Sonenshein
Journal:  J Biol Chem       Date:  1989-04-25       Impact factor: 5.157
View more
  2 in total

1.  Aponecrotic, antiangiogenic and antiproliferative effects of a novel dextran derivative on breast cancer growth in vitro and in vivo.

Authors:  Mélanie Di Benedetto; Anna Starzec; Bruno M Colombo; Dominique Briane; Gérard Y Perret; Michel Kraemer; Michel Crépin
Journal:  Br J Pharmacol       Date:  2002-04       Impact factor: 8.739

2.  The suppression of fibroblast growth factor 2/fibroblast growth factor 4-dependent tumour angiogenesis and growth by the anti-growth factor activity of dextran derivative (CMDB7).

Authors:  R Bagheri-Yarmand; Y Kourbali; C Mabilat; J F Morère; A Martin; H Lu; C Soria; J Jozefonvicz; M Crépin
Journal:  Br J Cancer       Date:  1998-07       Impact factor: 7.640
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.